Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.72 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.68 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.68 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.68 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL30751027 | 1.00 | P2RY1 (0.72) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL22498771 | 1.00 | P2RY1 (0.72) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL27776323 | 0.99 | P2RY1 (0.73) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL28987699 | 0.99 | P2RY1 (0.71) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL27614291 | 0.98 | P2RY1 (0.71) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL584344 | 0.98 | P2RY1 (0.71) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL6046207 | 0.98 | P2RY1 (0.71) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL7709477 | 0.97 | P2RY1 (0.72) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL27718390 | 0.97 | P2RY1 (0.72) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL28200474 | 0.97 | P2RY1 (0.70) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4705328-A2 | METHODS AND PLATFORM RELATED TO FLUORESCENT PROTEIN BIOSENSORS | Board of Regents, The University of Texas System (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025122455-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) FOR VEGF MODULATION | INVIRSA, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4561700-A1 | OPHTHALMIC SUSPENSION VEHICLES AND RELATED METHODS FOR PHARMACEUTICAL INGREDIENT DELIVERY | Willis, Timothy R. (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119859165-A | Adenosine diphosphate ribose polypeptide linked by oxy-glycoside bond, and synthetic method and application thereof | 河南师范大学 | 2025-04-22 | — | — | CN | claimed |
| CN-119604275-A | Ophthalmic suspension vehicles for drug ingredient delivery and related methods | 蒂莫西·R·威利斯 | 2025-03-11 | — | — | CN | claimed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2024229346-A2 | METHODS AND PLATFORM RELATED TO FLUORESCENT PROTEIN BIOSENSORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-2370112-A2 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PRATICLES AS SCAFFOLDS FOR TISSUE REGENERATION | Schubert Holdings LLC (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010060104-A2 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PRATICLES AS SCAFFOLDS FOR TISSUE REGENERATION | MOMA THERAPEUTICS (US) | 2010-05-27 | — | — | WO | claimed |
| EP-1259240-B8 | AGENTS, SUCH AS NICOTINAMIDE OR CADPR FOR THE TREATMENT OF SKIN DISORDERS | DERMIPSOR LTD (IL) | 2007-05-09 | — | — | EP | claimed |
| US-20050276762-A1 | Topical compositions containing 5'-adenosine-diphosphate ribose | ABBOTT LABORATORIES | 2005-12-15 | — | — | US | claimed |
| US-6558900-B2 | Screening for modulators of apoptosis; obtain supernantant extract from cells, incubate with modulator, compare to control, evaluate response to apoptosis | EMORY UNIVERSITY | 2003-05-06 | — | — | US | claimed |
| EP-1259240-A2 | AGENTS, SUCH AS NICOTINAMIDE OR CADPR FOR THE TREATMENT OF SKIN DISORDERS | Harel, Avikam (IL) | 2002-11-27 | — | — | EP | claimed |
| WO-2001051051-A2 | AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS | HAREL AVIKAM (IL) | 2001-07-19 | — | — | WO | claimed |
| US-5763180-A | In vitro assay for carcinogens using phenotypic transformation of human cells | VIRATEST CARCINOGEN MONITORING LTD. (CA) | 1998-06-09 | — | — | US | claimed |
| EP-0229674-B1 | Test to determine predisposition or susceptibility to DNA associated diseases | PERO RONALD W (US) | 1994-06-22 | — | — | EP | claimed |
| US-4012570-A | ADP-RIBOSE(ADENOSINE DIPHOSPHATE RIBOSE)-POLYMER MATRIX FOR USE IN AFFINITY CHROMATOGRAPHY | DEAN PETER DUNCAN GOODEARL | 1977-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050276762-A1 | Topical compositions containing 5'-adenosine-diphosphate ribose | ADAR, ADORA2A, ADORA1 | P2RY1 64/4885P2RX1 143/4885P2RX3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.